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Using a functional approach to investigate the epige-
netics of type 2 diabetes (T2D), we combine three
lines of evidence—diet-induced epigenetic dysregu-
lation in mouse, epigenetic conservation in humans,
and T2D clinical risk evidence—to identify genes
implicated in T2D pathogenesis through epigenetic
mechanisms related to obesity. Beginning with
dietary manipulation of genetically homogeneous
mice, we identify differentially DNA-methylated
genomic regions. We then replicate these results in
adipose samples from lean and obese patients pre-
and post-Roux-en-Y gastric bypass, identifying
regions where both the location and direction of
methylation change are conserved. These regions
overlap with 27 genetic T2D risk loci, only one of
which was deemed significant by GWAS alone.
Functional analysis of genes associated with these
regions revealed four genes with roles in insulin
resistance, demonstrating the potential general util-
ity of this approach for complementing conventional
human genetic studies by integrating cross-species
epigenomics and clinical genetic risk.
INTRODUCTION
Type 2 diabetes mellitus (T2D) is a metabolic disorder with a
rapidly increasing worldwide prevalence. T2D affects 300 million138 Cell Metabolism 21, 138–149, January 6, 2015 ª2015 Elsevier Inadults worldwide, and that number is predicted to rise to above
430 million by 2030 (Chen et al., 2012). Although T2D has a sig-
nificant genetic risk component, as determined by genome-wide
association studies (McCarthy, 2010), the heritability estimate is
only 21% when looking across all age groups (Almgren et al.,
2011). These low heritability estimates, coupled with the rapid
increase in worldwide prevalence, suggests a strong role for
environmental risk factors. As an example, recent work on the
efficacy of Roux-en-Y gastric bypass (RYGB) as a treatment
for obesity has found that this procedure can have a profound
positive effect on T2D-related metabolic indicators (Mingrone
et al., 2012).
Epigenetics, the study of non-DNA sequence-based infor-
mation that is replicated during cell division, such as
DNA methylation, has been suggested as a natural integrator
of genetic susceptibility and environmental exposure in
common disease (Bjornsson et al., 2004). Epigenetics has
also attracted considerable scientific and lay attention due to
its dynamic nature, association with common disease (Cui
et al., 2003), and reversibility under targeted therapies (Sharma
et al., 2010).
Most common human diseases are explained to a very limited
degree by known individual common genetic variants, with
3.4% of risk profile score explained for psychiatric disorders
like schizophrenia (Schizophrenia Working Group of the Psychi-
atric Genomics Consortium, 2014) and 10.7% for T2D (Global
Lipids Genetics Consortium et al., 2013). This combination of
limited genetic causality, environmental influence, and persis-
tence over long time periods suggests a likely role for epige-
netics in common human disease. However, epigenetic studies
have their own limitations, including the need in most cases to
use cells appropriate to the disease under study, confoundingc.
Table 1. Genome-wide Significant Mouse DMRs
Tissue Analysis q val < 0.05 q val < 0.1
Adipocytes Diet 232 448
Weight 183 288
Fasting glucose 235 571
GTT 0 3
ITT 294 419
q values generated based upon comparison of observed DMR areas
to areas generated by 1,000 random permutations of phenotype/
methylation associations. See also Table S1 for a full list of all
mouse DMRs.effects such as age, and the often considerable difficulty in
designing replication sets, which are much easier in purely ge-
netic studies because of the universality of the sample type
(DNA from blood). A number of methodologies have been devel-
oped by our group and others to adjust for cell-type composition,
confounding variables, and replication studies (which are typi-
cally much smaller) (Houseman et al., 2012; Liu et al., 2013;
Montan˜o et al., 2013).
There have been limited epigenetic analyses of T2D and asso-
ciated metabolic traits thus far. Studies of pancreatic islets have
found methylation differences between T2D patients and nondi-
abetic controls (Dayeh et al., 2014). Similar changes have also
been found in peripheral blood leukocytes from obese humans
early after RYGB (Kirchner et al., 2014). Two studies examining
DNA methylation related to exercise and T2D status found
epigenetic changes overlapping the TCF7L2 locus (Ro¨nn et al.,
2013; Toperoff et al., 2012). Finally, one study that examined
methylation in skeletal muscle from obese and lean subjects at
14 individually selected loci found that methylation in obese sub-
jects reverted to leanmethylation levels after RYGB (Barres et al.,
2013).
Here, we established an approach utilizing two species to
identify candidate genes involved in obesity and T2D through
epigenetic mechanisms. We first examined the epigenetic
consequences of a high-fat diet in a carefully controlled exper-
imental mouse obesity setting. We then replicated across
species—in humans—by analyzing adipose tissue from a cohort
that both reproduces and reverses a phenotype similar to the
obese mouse. The use of samples from the same subjects
pre- and post-RYGB allows a human isogenic comparison of
the effect of obesity-induced metabolic disturbances. This
cross-species approach exploits the power of evolutionary
selection, whose mechanisms have survived the 50 million
year separation between mouse and human, in a more compre-
hensive manner than simple replication from human set to
human set, and may better identify functionally important envi-
ronmental targets. We lastly stratified these cross-species
obesity-associated regions using genetic association data
from a large genome-wide association study (GWAS) for T2D
to more directly link our obesity-derived phenotypes with human
T2D. As a result of this approach, we are able to identify four
genes with roles in insulin resistance, suggesting that this
cross-species approach provides a powerful experimental sys-
tem for identifying the genomic variation associated with com-
mon disease.CellRESULTS
Alterations in DNA Methylation in Mouse Adipocytes
Produced by High-Fat Diet
To detect DNA methylation differences, we used the compre-
hensive high-throughput array-based relative methylation
(CHARM) method, which in its current form can assay over
5 million CpG sites in mouse and 7.5 million CpG sites in human.
In 12 adipocyte samples extracted from mouse adipose tissue,
we found 232 differentially methylated regions (DMRs) corre-
lated with diet status (Table 1). As an example, when comparing
adipocytes from high-fat-fed mice versus low-fat-fed mice, we
found hypermethylation overlying the promoter of phosphoenol-
pyruvate carboxykinase 1 (Pck1, Figure 1A). PEPCK, the product
of Pck1, catalyzes a rate-limiting step in gluconeogenesis, is
essential for lipid metabolism in adipose tissue, is known to be
regulated by insulin, and has been linked to lipodystrophy and
obesity in mice (Beale et al., 2004).
In addition to the high-fat versus low-fat analysis, even more
DMRs were detected when analyzing methylation differences
related to the metabolic phenotypes of body weight, fasting
glucose, and insulin and glucose tolerance test area-under-
curve (ITT/GTT AUC) values (Table 1 and Table S1). One example
of a mouse GTT-associated DMR is in the Fasn gene, which pro-
duces fatty acid synthase. Most DMRs found were significantly
associated with more than one trait, which is not entirely unex-
pected as the phenotypes themselves are highly correlated
(Figure S1).
We additionally examinedDNAmethylation in pancreatic islets
purified from whole mouse pancreata and hepatocytes ex-
tracted frommouse liver tissue.We found significant correlations
between methylation and mouse diet and weight in pancreatic
islets and correlations between methylation and weight and ITT
in hepatocytes (Table S1).
Pooling tissues together and surveying for DNA methylation
changes in common across tissues yielded no significant
results.
Gene Ontology for Mouse DMRs
We implemented gene set analyses to assess the overall biolog-
ical importance of the DNA methylation changes we observed in
mouse adipocytes. The genome-wide significant adipocyte
DMRs were near genes that were significantly overrepresented
in lipid metabolic and immune/inflammatory pathways com-
pared to the background list of genes represented on our array,
with enrichment q values < 9.7 3 103 (Table S2). Examining
hyper- and hypomethylated DMRs separately in high-fat-fed
obese mice, we observed that the metabolic pathway enrich-
ment was derived from genes near hypermethylated DMRs,
while the inflammatory pathway enrichment was present mainly
in genes near hypomethylated DMRs.
Inflammatory and immune-related systems are known to be
upregulated in adipocytes specifically in both obesity and
T2D (Hotamisligil, 2010). Similarly, recent work has shown adi-
pose de novo lipogenesis downregulation associated with
metabolic dysfunction (Roberts et al., 2009). These pathways,
however, have not previously been shown to be significantly
associated with methylation changes in a diet-induced obesity
phenotype.Metabolism 21, 138–149, January 6, 2015 ª2015 Elsevier Inc. 139
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Figure 1. Genome-wide Significant Methylation Changes Related to Diet-Induced Obesity in C57BL/6 Mice
(A) Two genome-wide significant DMRs are hypermethylated in adipocytes purified from mice raised on a high-fat diet. Each point represents the methylation
level in adipocytes from an individual mouse at a specific probe, with smoothed lines representing group methylation averages. These points are colored blue for
lean mice and red for obese mice.
(B) Bodyweight (grams) and glucose tolerance (AUC) are associatedwithmethylation in adipocytes at genome-wide significant levels. Each point in the top panels
represents oneprobe,with the y axis representing thePearsoncorrelation coefficients of the probeswith theanalyzedphenotype.Dotted lines represent the extent
of the DMR as generated automatically via CHARM. The bottom panels display gene location information for the chromosomal coordinates on the x axis.Methylation Replication in Mice and Associated Gene
Expression Studies
We then tested for replication of the methylation results at nine
DMRs in adipocytes and three DMRs in pancreatic islets in an in-
dependent set of 18 mice (Figure 2A and Table S3). The 625
genome-wide significant adipocyte DMRs have FDR q values
ranging from 0.004 to 0.05. In order to determine whether our re-
sults would replicate throughout this range, we examined a sub-
set of DMRs with levels of statistical significance that spanned
from the most significant to just below the 0.05 cutoff. Mice
used in the replication set were also reared on a high-fat diet
but were separate from those used for CHARM. Nine mouse
adipocyte DMRs were assayed by bisulfite pyrosequencing.
Eight of these regions had at least one CpG showing significant
differential methylation in the same direction as detected by
CHARM.
Although these were fractionated cells under investigation, to
further ensure that the results were not due to cell-type shifts in140 Cell Metabolism 21, 138–149, January 6, 2015 ª2015 Elsevier Inthe high-fat-fed obese mice resulting from the infiltration of im-
mune cells into adipose tissue, we used quantitative PCR
(qPCR) to characterize the expression of multiple macrophage-
and adipocyte-specific markers in our purified adipocyte
samples from low-fat-fed and high-fat-fed mice. We saw no sig-
nificant change in the levels of expression of the macrophage
(inflammatory) markers F4/80, Cd14, or Cd68, and we did see
the expected obesity-related within-adipocyte changes of the
adipocyte markers AdipoQ and Ccl2 (Table S4).
To examine whether these methylation changes between
high-fat- and low-fat-fed mice involved changes in the expres-
sion of nearby genes, we used quantitative PCR to examine
the expression of 13 genes near genome-wide significant
DMRs (Figure 2B). We used qPCR to examine mRNA from the
same adipocytes and mice that were analyzed by CHARM. Of
the 13 genes examined, 9 showed significant changes in
mRNA expression in the opposite direction as methylation
changes (Figure 2B).c.
AB
Figure 2. Replication of Mouse Methylation Changes in Additional Mice and Associated Gene Expression Changes
(A)Methylation changes observed after CHARManalysis at two genome-wide significant DMRs are replicated using bisulfite pyrosequencing. Red boxes indicate
CpGs assayed in pyrosequencing. For the lower pyrosequencing plots, the y axis representsmethylation, and individual CpGs are plotted along the x axis. Purple
dots represent control DNA artificially methylated to have 0%, 25%, 50%, 75%, and 100% methylation.
(B) Gene expression changes for genes near genome-wide significant mouse adipocyte DMRs. RNA levels were normalized to same-sample 18S RNA mea-
surements and are displayed as (CT [high-fat samples]  CT [low-fat samples])2. Error bars represent standard error of the CT differences between groups.
*p < 0.05, **p < 0.005. The direction of the genome-wide significant CHARM DMR closest to the gene is denoted below the gene names; + and  represent
regions hyper- or hypomethylated in the high-fat samples, respectively. See also Figure S2 for whole-genome gene expression correlations and Table S4 and
Table S5 for pyrosequencing and tissue purification, respectively.Furthermore, we assessed whether these DNA methylation
changes correlated with previously published genome-wide
gene expression data in a similar cohort (Xu et al., 2003). WeCellsaw significant inverse correlations between diet-relatedmethyl-
ation changes and diet-related gene expression changes (Fig-
ures S2A and S2B). These results compare favorably to otherMetabolism 21, 138–149, January 6, 2015 ª2015 Elsevier Inc. 141
functional analyses of discovered DMRs (Kim et al., 2010). Taken
together, these data show that we find robustly significant DMRs
in mice that correlate with metabolic traits, that these DMRs
replicate in separate animals, and that methylation at many of
these regions appears to have a functional effect on gene
expression.
Mouse DMRs Replicated Evolutionarily in Human
Adipose Tissue
We reasoned that many functionally relevant DMRs in mice
exposed to a high-fat diet serve an important metabolic function
that would be conserved across species and often susceptible
to similar environmental cues. Therefore, to determine whether
the methylation changes observed in mouse adipocytes could
be replicated in an evolutionarily divergent cohort, we performed
CHARM analysis on human subcutaneous adipose tissues from
7 lean subjects and 14 obese, sex-matched, insulin-resistant
subjects of the same age range, as well as 8 obese subjects
post-RYGB.
We first examined the replication of mouse adipocyte DMRs in
human adipose tissue from obese versus lean. We observed
very strong overlap between DMRs in human obese versus
lean tissue and DMRs in high-fat-fed versus low-fat-fed mouse
adipocytes (all p < 1015, Figure S3A, rightmost five bars),
showing that there is a strong correlation between areas that
are regulated by methylation in metabolic dysfunction in both
mice and humans.
Next, in order to determine which mouse methylation changes
would replicate in human, we determined that out of a total of
625 genome-wide significant mouse adipocyte DMRs, 576 had
homologous regions on the human genome (hg19), calculated
via the liftOver UCSC tool (Hinrichs et al., 2006), and 497 had hu-
man CHARM probes within 5 kb. This is a remarkably high frac-
tion (86.3%), suggesting that our assay method, CHARM, is
highly comprehensive, and also that the location of CpG regions
is strongly conserved in evolution. Of the 497 conserved DMRs,
249 (50.3%) showed significant differential methylation (p < 0.05)
between obese and lean people (Table S5). These numbers were
similar when analyzing differential methylation before and after
RYGB surgery (227 out of 497). As a final restrictive step in using
humanmethylation to validate ourmouse results, we determined
that 170 (68%) of these regions had a consistent direction of
methylation change between high-fat-fed obesemice and obese
humans, such that if a particular region had higher methylation in
high-fat-fed mice, that region would also have higher methyl-
ation in obese humans and vice versa.
When more restrictive human methylation significance cutoffs
are used, the percentage of regions with consistent directionality
(true positive rate) rises, but the total number of retained regions
drops, with 67/77 (87%) directionally consistent at human
obesity p values < 0.005, and 25/25 (100%) consistent at
p values < 0.0005 (Figure S3B). All 170 directionally conserved
regions were associated with the metabolic phenotypes of fast-
ing glucose, GTT, and/or ITT in addition to mouse diet status.
Furthermore, 134 of these regions had consistent directions of
methylation change between both lean-obese and pre-/post-
RYGB samples (e.g., higher in obesity and presurgery and vice
versa), and a further 105 had postsurgery methylation values
that were in between lean and presurgery methylation values,142 Cell Metabolism 21, 138–149, January 6, 2015 ª2015 Elsevier Ini.e., regions where methylation in obese subjects appeared
to revert toward a lean phenotype after surgery (enrichment
p = 2.8 3 103).
In Figure 3, we present two regions that have significant
methylation changes in human adipose tissue, are in homolo-
gous regions of the genome as mouse DMRs, are directionally
consistent with the mouse DMRs, and have human postsurgery
methylation levels that havemoved closer to the lean phenotype.
These regions are over two genes: ADRBK1 (adrenergic, beta,
receptor kinase 1, Figure 3A) and KCNA3 (potassium voltage-
gated channel, shaker-related subfamily, member 3, Figure 3B).
We also assessed whether the human adipose DNA methyl-
ation changes correlated with previously published human
genome-wide gene expression data from obese and lean indi-
viduals (Arner et al., 2012). As with our mouse data, we saw a
highly significant inverse correlation between obesity-related
methylation changes and obesity-related gene expression
changes (Figures S2A and S2B, right panels).
We performed a similar mouse-human comparison in pancre-
atic islets using published DNAmdata from T2D and control sub-
jects (Dayeh et al., 2014), showing that 67% (odds ratio = 7.2,
p = 7.2 3 106) of the mouse pancreatic islet DMRs that repli-
cated in the human data had methylation change in the same
direction and that these probes were far more associated with
human T2D status than the rest of the probes on the array
(p = 1.18 3 109, Figure S3C), demonstrating that our mouse-
derived islet DMRs are enriched for potential epigenetic alter-
ation in human T2D. Finally, we also validated multiple mouse
hepatocyte DMRs in human liver tissue, with 62.5% replicating
(Table S3).
Genetic Risk Loci Association with Overlapping Regions
of Human and Mouse Methylation Changes
We incorporated data from human GWAS for T2D using two
complementary approaches that allow further characterization
of our candidate obesity-related DMRs. GWAS summary statis-
tics were obtained from the DIAGRAM (Diabetes Genetics
Replication and Meta-Analysis) T2D genome-wide association
meta-analysis, comprising data from 12 separate GWAS studies
totaling 12,171 T2D cases and 56,682 controls (http://www.
diagram-consortium.org). We first directly explored the associa-
tion between genes with obesity-related DMRs and genes
conferring clinical genetic risk for T2D by calculating statistical
enrichment of the GWAS regions overlapping our DMRs. We
found marginally significant enrichment for adipose DMRs
among at least marginally significant GWAS signals (GWAS
p value cutoffs starting with p < 106, corresponding to enrich-
ment p values ranging from 0.0048 to 0.0165, Table S6). Given
the small number of directly overlapping regions, these results
are likely strongly influenced by the strength of the TCF7L2
signal. While much of the early literature on TCF7L2 focused
on its role in pancreatic islets, there is growing evidence that ex-
trapancreatic effects may contribute to the T2D phenotype at
this locus (Nilsson et al., 2014).
We further examined statistical enrichment in the context of
regulatory networks involving genes implicated in GWAS. Genes
at 23 genome-wide significant GWAS signals (usually the gene
nearest to the lead SNP) were directly (one-step) connected to
genes near DMRs either by transcriptional control or directc.
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Figure 3. Overlapping Methylation Changes in Human and Mouse Adipose Tissue
(A and B) Two genome-wide significant DMRs found in mouse adipocytes (top panels) over Adrbk1 (A) and Kcna3 (B) are shown along with the corresponding
methylation changes in human adipose tissue (bottom panels). For the panels denotingmethylation, each point represents themethylation level from an individual
mouse or human at a specific genomic location, with smoothed lines representing group methylation averages. y axis, methylation values. Below each
methylation plot is a panel showing genomic coordinates for the respective species and any genes at those coordinates. See also Figure S3 for tissue and species
overlaps and Table S6 and Table S7 for conserved adipose mouse DMRs in human and for enrichment between DIAGRAM and conserved DMRs, respectively.protein-protein interaction (Figure 4A). This amount of interaction
represents significantly more than expected by random chance
(p = 0.0206) (Figure S4) and demonstrates how genes implicated
by methylation appear to be acting in the same pathways as
genes implicated by GWAS. Similarly, expanding beyond one-
step connections, many of the 30 regions implicated by both
methylation data and GWAS are connected to genes identified
by the mouse-only and human-mouse analyses and act in the
same pathways (Figure 4B).
Given these results, we sought to further filter our obesity-
related DMRs down to the subset of genes likely associated
with T2D. We hypothesize that DMRs that overlap associated
marker SNPs for T2D can identify genes with epigenetic mecha-
nisms of risk in adipose tissue. Asmany of the DMRs overlapping
GWAS T2D loci with low p values implicate genes already known
to be involved in T2D, obesity, and related phenotypes, we there-
fore selected the subset of DMRs within genetic loci that had at
least marginal statistical association with T2D clinical risk.
This approach reduced the 170 regions of directionally consis-
tent and evolutionarily conserved methylation change in adipose
tissue using the SNP-level summary statistics of the DIAGRAMCellanalysis. In all, 30 cross-species and directionally conserved
adipose DMRs directly overlapped with 27 marker SNPs (or
close proxies with linkage disequilibrium > 0.8) that had some
evidence of association with T2D (at least p < 0.01, Table 2;
see Experimental Procedures). We also identified ten regions
where conserved pancreatic islet DMRs overlap with DIAGRAM
SNPs (Table S7).
In these final 30 regions, not only have we connected methyl-
ation change to obesity-induced metabolic phenotypes across
two species, but the association with T2D-associated SNPs
also provides a candidate mechanism for the methylation
changes observed in human obesity and RYGB surgery. These
27 identified SNPs could potentially explain up to 2.69% of ge-
netic T2D liability, though only one of these loci reached
genome-wide significance in DIAGRAM (Morris et al., 2012).
Even excluding this GWAS-positive loci (TCF7L2), which ex-
plains 1.12% of the variance alone, the remaining regions could
explain up to 1.57% of genetic variance in T2D susceptibility.
These data suggest that for at least some of these loci, genetic
variation underlies changes in methylation that are causal for
T2D risk. It is also possible that these regions are alsoMetabolism 21, 138–149, January 6, 2015 ª2015 Elsevier Inc. 143
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Figure 4. Diagrammatic Representation of the Interactions between Epigenetically Conserved andGenetically Associated Genes Implicated
in This Study
(A and B) Generated using QIAGEN’s Ingenuity IPA (Ingenuity Systems), these diagrams represent the connections between genes implicated in our analyses.
(A) Genes with genome-wide significant linkage to T2D in the DIAGRAM meta-analysis were connected to genes near directionally conserved cross-species
DMRs. Genes with no connections were dropped. (B) Starting with a set of 23 genes near T2D-associated directionally conserved cross-species DMRs, this
network was grown by adding genes near species-conserved and mouse-only genome-wide significant DMRs in order to represent one potential regulatory
network. Gene colors explained in within-figure legend. See also Figure S4 for the permutation analysis of the enrichment of interactions in (A).susceptible to environmental factors that influence local methyl-
ation and that they therefore serve to integrate genetic and
epigenetic effects.
Note that this filtering-based approach is independent of
assessing the statistical enrichment of T2D GWAS signal, either
at SNP or gene level, within our cross-species obesity-associ-
ated DMRs, an approach commonly used with GWAS summary
statistic data. This approach therefore does not diminish the
potential function of genes with GWAS-positive statistical asso-
ciation for T2D or of our DMRs that do not overlap with GWAS-
associated SNPs, for contributing epigenetically to obesity.
We hypothesized that one mechanism by which DNA methyl-
ation and genetic variation contribute to T2D risk may involve
enhancer activity. Using publicly available human enhancer
maps in 86 independent cell and tissue types (Hnisz et al.,
2013), we found that a striking proportion of DMRs mapped to
adipose nuclei enhancers and superenhancers (which had the
largest degree of overlap across all cell types). While the back-
ground proportion of overlap for CHARMwas 17.2% for adipose
enhancers and 3.8% for super enhancers, 40.6% (69 overlaps,
p = 1.58 3 1015) and 14.7% (25 overlaps, p = 5.72 3 1013)
of the directionally consistent 170 regions and 53.3% (16 over-
laps, p = 5.65 3 107) and 20% (6 overlaps, p = 3.24 3 105)
of the further 30 GWAS-associated regions above lie in adipose
enhancers and super enhancers, respectively (Table S8). Thus, a
major mechanism for methylation-mediated metabolic dysfunc-144 Cell Metabolism 21, 138–149, January 6, 2015 ª2015 Elsevier Intion is likely through epigenetic modification of enhancers. Note
that most of these enhancers were not previously known to be
related to T2D through conventional GWAS or other methods.
Functional Analysis of Genes Implicated by Cross-
Species Methylation
In order to establish that our cross-species method can identify
functional genes implicated in obesity, insulin resistance, T2D,
and related research, we functionally assayed five genes. We
selected genes with no prior association with metabolic pheno-
types and that had methylation reversion after RYGB. As RYGB
is a targeted, environmental therapy that improves multiple dele-
terious phenotypes including insulin sensitivity, we hypothesized
that this subset of our results would be the most likely to have an
effect on T2D- and obesity-related phenotypes. We then exam-
ined the physiological effect of altering the expression of these
genes on adipocyte cell culture models using insulin-stimulated
glucose uptake assays. This procedure canmeasure the respon-
siveness of adipocytes to insulin, a phenotype disrupted in
obesity. We assayed seven 3T3-L1 adipocyte cell lines, each
stably expressing shRNAs or expression plasmids correspond-
ing to one of the five selected genes or a suitable control. In order
to mimic the effects of a high-fat diet, genes hypermethylated in
high-fat adipocytes were knocked down, and genes hypomethy-
lated were overexpressed. Significant changes in glucose up-
take were found for four of these five (Figure 5B). Potential rolesc.
Table 2. Mouse-Human DMRs with Genetic T2D Risk Loci
Association
Gene name
Relative location
of DMR
Distance
to TSS
RYGB
reversion
DIAGRAM
p value
Tcf7l2 inside intron 43,058  4.90E-68
Tcf7l2 Inside intron 77,345  4.90E-68
As3mt overlaps 50 0 + 9.60E-06
Etaa1 Inside intron 618 + 4.70E-05
Tnfsf8 overlaps 50 0  0.00029
Plekho1 overlaps exon 4,965 + 0.00045
Tnfaip8l2 inside intron 337 + 0.00045
Akt2 inside intron 20,427  0.00049
DIAGRAM GWAS 0.001 cutoff
Lhfpl2 Inside intron 2,490 + 0.001
Mkl1 overlaps 50 0 + 0.0014
BC048644
(Car5a)
overlaps exon 146 + 0.0015
Rgs3 downstream 10,8842 + 0.0019
Fgd3 Inside intron 11,100 + 0.002
Stau1 overlaps 50 0 + 0.0022
Tmcc3 Inside intron 43,772 + 0.0025
Tbx3 inside exon 12,714 - 0.0029
Gstz1 Inside intron 10,332 + 0.0029
Taok3 Inside intron 549 + 0.0036
Bnip3 Inside intron 1,863  0.0039
Dlst overlaps 50 0 + 0.0053
Kcna3 Close to 30 2,192 + 0.0064
Cln8 Inside intron 3,055 + 0.0065
Cd37 exon 2,687 + 0.0069
Nfib Inside intron 100,380  0.0071
Pck1 promoter 453 + 0.0072
Pck1 overlaps 50 0 + 0.0072
Pcx inside intron 59,049 + 0.0073
Hoxd3 inside intron 7,307 + 0.0084
Cd33 overlaps 50 0 + 0.0087
Evl exon 157 + 0.0099
Shown are the names of the nearest gene to the mouse and human dif-
ferential methylation, the position of the DMR relative to the gene, the dis-
tance to the transcriptional start site (TSS), whether the direction of
methylation change (sign of smoothed effect statistic) post-RYGB sur-
gery reverts toward lean subject methylation levels (RYGB reversion),
and the p value of the T2D genetic association in the region. See also
Table S7 for an analogous table with the pancreatic islet results instead
and Table S8 for conserved adipose DMRs that overlap with adipose
enhancers.for all of these genes in modulating insulin sensitivity and resis-
tance are considered in the Discussion.
DISCUSSION
In mouse, we identified 625 genome-wide significant DMRs that
correlate with diet-induced obesity phenotypes in adipocytes.
Of these regions, 249 had significant conserved methylation
changes in human obesity, and 170 of these had the same direc-Celltion of methylation change in both species. Thirty of these DMRs
also overlapped with SNPs or nearby proxies that have been
associated with human T2D genetic risk. These data show that
DNA methylation changes in metabolic disease are conserved
across species and that this conservation overlaps genomic re-
gions where genetic polymorphisms have been associated with
T2D. Our approach combines three lines of evidence—epige-
netic dysregulation following high-fat diet in mouse, epigenetic
directional consistency in humans, and some evidence for clin-
ical risk of T2D—to identify genes likely functionally implicated
in the pathogenesis of T2D specifically through epigeneticmech-
anisms related to obesity.
In the present study, while we use nominal p value significance
to identify human methylation and GWAS results, we first
perform a multiple comparison correction in our initial set of
mouse DMRs using a false discovery rate algorithm. As there
is a growing awareness that the cumulative effect of common
SNPs with low minor-allele frequency scores potentially explain
large amounts of phenotypic variability beyond that of genome-
wide significant SNPs identifiable by GWAS (Yang et al., 2010),
approaches like ours that can use alternative methods to identify
significant areas of potential genetic risk are necessary. The
unique SNPs in these regions potentially account for 2.76% of
T2D genetic variance, almost half of which is known by purely
genetic analysis and may be epigenetically mediated.
We observed significant changes associated with 4 out of
5 genes assayed by insulin-stimulated glucose uptake assay, a
common indicator of insulin resistance. Screens using this assay
and performed on sample sets not enriched for genes in gluco-
insulinemic pathways have found a far smaller percentage of
genes that will alter glucose uptake (10%) (Tang et al., 2006),
indicating that our method can successfully select potential tar-
gets with a much higher than random probability of affecting in-
sulin sensitivity.
Three of the genes that we found had altered glucose uptake
fell into the classical inverse methylation-gene expression corre-
lation: Mkl1, Plekho1, and Tnfaip8l2 were all hypomethylated in
high-fat-fed mice and obese humans, had increased gene
expression in corresponding subjects, and, when these genes
were overexpressed in cell culture adipocytes, exhibited
decreased glucose uptake in response to insulin, which would
fit with the increased insulin resistance commonly observed in
obesity and diabetes. While none of these genes has previously
published roles in insulin resistance, several have suggestive
links to metabolic phenotypes. Mkl1 is known to be a transcrip-
tional coactivator of serum response factor (SRF), which been
associated with insulin resistance in skeletal muscle (Jin et al.,
2011). Similarly, PLEKHO1 has recently been shown to inhibit
AKT/PI3K signaling (Zhang et al., 2014), a pathway known to
be involved in insulin signaling. With regards to the direction of
glucose uptake change, we note that insulin signaling induces
both positive and negative feedback within affected cells (Gual
et al., 2005), and without a methylation-gene expression candi-
date mechanism it is not possible to determine which feedback
loop the methylation changes are involved with.
It is worth noting that as these genes did not contain common
variants that passed the genome-wide significant GWAS
threshold, they would not have been identified by GWAS alone.
Similarly, only 4 out of these 5 genes had significant geneMetabolism 21, 138–149, January 6, 2015 ª2015 Elsevier Inc. 145
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Figure 5. Overexpression and shRNA-
Mediated Knockdown of Selected Genes in
3T3-L1 Adipocytes
(A and B) Selected genes from the set of 30 spe-
cies conserved and T2D-SNP overlapping adi-
pose DMRs were either stably overexpressed (A)
or knocked down with shRNA (B). Glucose uptake
is plotted as fold difference from normal, error bars
represent standard error, and significance was
determined by two-way ANOVA modified by
Bonferroni correction denoted as follows: * p <
0.05, ** p < 0.01, *** p < 0.001.
(C) DNA methylation and gene expression levels
for high-fat-fed mice and obese human versus
low-fat-fed mice and lean humans (e.g., ‘‘Y’’ in-
dicates hypomethylation/lower gene expression in
high-fat-fed and obese compared to low-fat-
fed and lean). Bold arrows indicate significant
changes.expression changes. This functional assay illustrates how our
method of combining cross-species methylation data with
GWAS results for common SNPs can implicate genes that would
not have been detected otherwise.
Recent work in our laboratory has identified regions of the
genome where DNAmethylation acts to mediate a genetic effect
on rheumatoid arthritis (Liu et al., 2013), and the methylation
changes in obese humans could potentially act in an analogous
role. Our results in obese and insulin-resistant mouse models,
however, identify methylation differences even between inbred
mice and thus are definitively the result of environmental stimuli
rather than a genetic underpinning. The fact that we see many of
these same methylation changes in obese humans, and that
these changes are located over regions with known genetic links
to T2D, implies that DNA methylation levels could be integrating
and mediating genetic and environmental causes of metabolic
disease at specific genomic loci.
It is encouraging that many of the genes described here show
pathway relationships to known genetic associations (Figure 4).
For example,PRC1, a regulator of cytokinesis, is associatedwith
T2D by a genome-wide significant DIAGRAM result, but it has no
known connection to any other gene implicated by genome-wide
significant DIAGRAM loci. Its transcription, however, is regulated
by FOXO1, an important transcription factor in gluconeogenesis,
insulin signaling, and adipocyte differentiation that we find to be
differentially methylated in both mouse and human obesity.
FOXO1 is in turn regulated by TCF7L2, one of the strongest
GWAS results. Furthermore, combining genes from all levels of
this study creates potential regulatory networks that include
genes with known involvement in T2D, but also incorporate
closely connected genes with no previously known obesity or
T2D association that are shown to be involved with obesity
and insulin resistance in this story (Figure 4B). Some of these
genes, such as FASN and APP, appear to be loci in this network
and could represent potentially important targets.
There are many approaches for and important applications of
interrogating the association of functional and genetic elements146 Cell Metabolism 21, 138–149, January 6, 2015 ª2015 Elsevier Inusing GWAS summary statistics (ENCODE Project Consortium,
2012; Jostins et al., 2012; Nicolae et al., 2010), but our approach
is unique in its leverage of carefully controlled biological systems
to directly integrate cross-species functional epigenomics and
clinical genetic risk by stratification. This work, of course, does
not address or diminish the many GWAS associations that are
not associated with methylation changes. Additionally, it is
important to note that while we do not directly address the issue
of methylation causality in this study, causality is, at the least,
multi-tiered. Our functional data certainly indicate that these
epigenetic changes are functionally proximate to T2D-relevant
phenotypes and therefore important for discovery and for clinical
translation. Current systems biology literature challenges con-
ventional notions of causality as there is both positive and nega-
tive feedback in most complex living systems (Noble, 2012).
The approach described in this studymay have broad applica-
bility to identify candidate genes that may better dissect mecha-
nisms and potential routes of treatment in common human
disorders, such as cancer and cardiovascular disease. The
accessibility of a limited cohort of relevant patients with well-
characterized clinical materials before and after disease expo-
sure is plausible for cross-species replication. This type of
analysis can generate a reliable, functional candidate disease
gene set that can be used to interrogate SNP data sets and
lend additional support to specific targets that would not ordi-
narily pass the genome-wide correction threshold. The end
result is a process that can integrate information from multiple
complementary sources to identify potential targets essential
for the pathogenesis of common diseases, such as obesity or
T2D, that do not involve highly penetrant single genes, but rather
arise from multiple defects along pathways that integrate ge-
netic, epigenetic, and environmental cues.EXPERIMENTAL PROCEDURES
For full details of all methods (and primer sequences), please see Supple-
mental Experimental Procedures.c.
Mouse Sample Preparation
All animal protocols were approved by the Institutional Animal Care and Use
Committee of The Johns Hopkins University School of Medicine. Male
C57BL/6 mice were purchased from Charles River. Mice were fed a high-fat
diet ormatched control low-fat diet. Diet was provided for a period of 12weeks,
beginning at 4 weeks of age. At termination of the study, animals were fasted
overnight and euthanized, and tissues were collected.
Intraperitoneal Glucose and Insulin Tolerance Tests
Cohorts of mice (between 20 and 24 weeks of age) were injected with glucose
or insulin. Animals were fasted overnight (16 hr) prior to the glucose tolerance
test. For the insulin tolerance test, food was removed 2 hr prior to insulin injec-
tion. Serum samples were collected and glucose concentrations determined
at six time points after injections.
Mouse Hepatocyte Isolation
A protocol for primary hepatocyte isolation was performed using Collagenase
(BD Biosciences) and gradient centrifugation as adapted from previously pub-
lished methods (Berry and Friend, 1969; Li et al., 2010).
Mouse Primary Adipocyte Isolation
Mature adipocytes were isolated from mouse fat pads using Collagenase
(Sigma) and resuspension washes as previously described (Stahl et al., 2002).
Pancreatic Islet Isolation
Pancreatic islets used for CHARMwere isolated as previously described (Hus-
sain et al., 2000). For the pancreatic islets used in the replication set, whole
pancreases were obtained from high-fat-fed and low-fat-fed mice, stained
for insulin, and cryosectioned into 8 mm sections, and then laser-capture
microdissection was used to isolate pancreatic islets.
3T3-L1 Transduction and Transfection
3T3-L1 cells were transducted with Sigma Mission lentiviral particles (Sigma)
and transfected with overexpression plasmids using Lipofectamine 3000
(Life Technologies) as per the respective manufacturers’ protocols.
Cell Culture and Glucose Uptake Assay
3T3-L1 cell lines (ATCC) were maintained and differentiated as per manufac-
turer’s protocol, and glucose uptake assays were performed on differentiated
knockdown and overexpression lines.
Clinical Cohort
This study was approved by the Regional Ethics Committee of Stockholm.
All participants provided informed oral and written consent. Clinical
characteristics are shown for the obese men before and after RYGB
surgery (n = 14, 8, respectively) and nonobese (normal weight) men with a
similar age range (n = 7). Full information for human subjects can be found in
Table S9.
Human Sample Surgery and Subcutaneous Adipose Tissue Biopsies
A standard laparoscopic RYGB with a 1 m Roux limb was performed. Subcu-
taneous abdominal adipose biopsies (50–100 mg) were obtained from the
obese and nonobese (normal weight) subjects. Biopsies were obtained at
the beginning of RYGB surgery (obese subjects) or elective laparoscopic cho-
lecystectomy (lean subjects). Biopsies taken from the obese subjects 6months
after RYGB surgery were obtained after an overnight 12 hr fast from the same
surgical incision as the initial biopsy.
CHARM DNA Methylation Analysis
Genomic DNA from all samples was purified with the MasterPure DNA purifi-
cation kit (Epicenter) following the manufacturer’s protocol. Genomic DNA
was fractionated, digested with McrBC, gel-purified, labeled, and hybridized
to a CHARM microarray as described (Ladd-Acosta et al., 2010). The array
design specifications are freely available on our website (http://rafalab.dfci.
harvard.edu/). Subsequent technical preprocessing, normalization, and
correction for batch effects were performed as previously described (Jaffe
et al., 2012).CellBisulfite Pyrosequencing
Genomic DNA from each replication sample was bisulfite treated and PCR
amplified using nested primers. DNA methylation was subsequently deter-
mined by pyrosequencing with a PSQ HS96 (Biotage) as previously reported
(Migheli et al., 2013). Artificially methylated control standards of 0%, 25%,
50%, 75%, and 100% methylated samples were created using mixtures of
purified and SssI-treated whole-genome amplified genomic DNA.
Quantitative PCR Analysis
Validated primers for all genes were taken from PrimerBank (Wang and Seed,
2003) and synthesized by Integrated DNA Technologies. RNA was extracted
with TRIzol reagent (Life Technologies), cDNA was created with Quantitect
Reverse Transcriptase Kit (QIAGEN), and qPCR was performed with Fast
SYBR Green (Applied Biosystems) on a 7900HT Fast Real-Time PCR system
(Applied Biosystems). RNA levels were normalized to same-sample 18S
RNA levels.
GO Annotation
We analyzed GO annotation using the GOrilla tool (Eden et al., 2009). Enrich-
ment was calculated by comparing genes identified from our analysis to a
background of all genes detectable on the appropriate array.
Whole-Genome Gene Expression Analysis
Whole-genome gene expression data for mouse and human analogs of our
study were downloaded from GEO (Barrett et al., 2013). The mouse data
were already preprocessed, and the human data were preprocessed using
robust multiarray averaging (RMA) from the Affy R library (Bioconductor).
The gene expression data were then matched against the DMRs closest to
corresponding genes, the log fold change (logFC) of the gene expression
was plotted against the average value of the smoothed effect estimate within
the DMR, and p values were generated using t tests based on Pearson’s cor-
relation coefficient.
Enrichment between Human and Mouse DMRs
The liftOver tool from the UCSC genome browser transformed the coordinates
from the human DMRs from the hg19 human genome to the mm9 mouse
genome, as implemented in the rtracklayer Bioconductor package (Lawrence
et al., 2009). For each pair of DMR lists, one from the two lifted-over human
DMRs and another from the 25 mouse trait DMRs (Table S1), we calculated
the number of DMRs given within specific p value significance levels, and
also the number that overlapped within 5 kb across species. Enrichment tests
were chi-square tests based on the number of species-overlapping significant
DMRs, then DMRs only significant within each species, and finally the number
of lifted probe groups that were not significant in either species.
Cross-Species Statistical Analysis
We combined significant adipocyte mouse DMRs (at FDR < 5%) across the
five traits (glucose, GTT, ITT, weight, and diet) by retaining the maximal coor-
dinates over overlapping cross-trait DMRs, resulting in 625 independent
DMRs associated with at least 1 trait in adipocytes in mouse. These regions
were lifted over from the mouse mm9 genome build to the human hg19
genome build as implemented in the rtracklayer Bioconductor package (Law-
rence et al., 2009). These DMRswere annotated to the nearest humanCHARM
probe group based on the annotation within 5 kb. We then computed a differ-
ence and corresponding p values in obese versus lean and then in obese hu-
mans pre- versus post-RYGB surgery using linear regression and retained the
minimump value, number of probes with p < 0.05, and the slope at the smallest
p value within each of the mapped DMRs.
DIAGRAM GWAS Analysis
We integrated GWAS results into the mouse-human DMRs by obtaining
publicly available results from the DIAGRAM meta-analysis (http://
diagram-consortium.org/downloads.html; Stage 1 GWAS: Summary Statis-
tics download).
We estimated the variance in disease susceptibility based on the algorithms
provided in the Methods section of Morris et al. (Morris et al., 2012) and from
Wray et al. (Wray et al., 2010) using 1000 Genomes-derived risk alleleMetabolism 21, 138–149, January 6, 2015 ª2015 Elsevier Inc. 147
frequencies and assuming a disease prevalence of 8% for a given collection of
risk SNPs.
We assessed potential enrichment between the DMRs and the GWAS re-
sults using two complementary approaches. The first assessed the enrich-
ment in genome location between DMRs and the LD blocks from the GWAS
(Collado-Torres and Jaffe, 2014), and the second assessed enrichment in
gene symbols based on all genes directly connected (one-step) to genes
linked to T2D with genome-wide significance by the DIAGRAM meta-analysis
based on regulatory networks generated using QIAGEN’s Ingenuity IPA
(Ingenuity Systems).
ACCESSION NUMBERS
The GEO series record for the microarray data reported in this paper is
GSE63981.
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